ArticleAntimicrobial agents and chemotherapy2017
Roles of
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 92 citations in OpenAlex.
- Emergence ofVirulence · 2026Article
- Evaluation of Oxford nanopore sequencing for antimicrobial resistance surveillance inMicrobiology spectrum · 2026Article
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Phylogenetic diversification and fitness trade-offs of TetA variants in mediating eravacycline resistance inAntimicrobial agents and chemotherapy · 2026Article
- Emergence of azithromycin-resistant extensively drug-resistantFrontiers in microbiology · 2026Article
- Whole-Genome Insights Into Tigecycline-ResistantTransboundary and emerging diseases · 2026Article
- Article
- Transfer and Fitness of ISMicroorganisms · 2025Article
- Heteroresistance is associated with mutations during low concentration of tigecycline therapy in multiple-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2025Article
- Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2025Article
- Detection of CRISPR‒Cas and type I R-M systems inMicrobiology spectrum · 2025Article
- Article
- Article
- Hypervirulent Carbapenem-resistantInfection and drug resistance · 2025Review
- Epidemiology and resistance mechanisms of tigecycline- and carbapenem-resistantFrontiers in microbiology · 2025Article
- The investigation of molecular epidemiological characteristics and resistance mechanism of tigecycline resistantFrontiers in cellular and infection microbiology · 2025Article
- ESKAPE in China: epidemiology and characteristics of antibiotic resistance.Emerging microbes & infections · 2024Review
- Analyzing Antibiotic Resistance in Bacteria from Wastewater in Pakistan Using Whole-Genome Sequencing.Antibiotics (Basel, Switzerland) · 2024Article
- Emergence of plasmid-borneMicrobiology spectrum · 2024Article
- Epidemiological and genomic characteristics of global blaNDM-carrying Escherichia coli.Annals of clinical microbiology and antimicrobials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is regarded as a last-resort treatment for carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.